Minerva Neurosciences (NERV) Reports Screening of 1st Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder
Tweet Send to a Friend
Minerva Neurosciences, Inc. (NASDAQ: NERV) today announced the screening of the first patient in a Phase 2b trial of MIN-117 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
